title: Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
abstract: In 2006, i.p. chemotherapy re-emerged as a controversial topic in debates about the optimal treatment for women with advanced epithelial ovarian cancer. In this paper, we address the rationale behind i.p. chemotherapy, the data supporting its use, the selection of appropriate patients for i.p. chemotherapy, how best to avoid and manage the toxicities observed with i.p. chemotherapy, and directions for future research.
authors.affiliation: Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Suite 7025, MSC 7436, Bethesda, Maryland 20892-7436, USA. trimblet@ctep.nci.nih.gov
authors.forename: Edward L
authors.initials: EL
authors.lastname: Trimble
authors.forename: Sharon
authors.initials: S
authors.lastname: Thompson
authors.forename: Michaele C
authors.initials: MC
authors.lastname: Christian
authors.forename: Lori
authors.initials: L
authors.lastname: Minasian
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral / Q000009:adverse effects; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000523:psychology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology; D018579:Patient Selection; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents